How Allergy Treatment Is Changing for Families

There has been a lot of discussion about recent changes to peanut allergy treatment. You may have seen that Palforzia is being discontinued in the UK for commercial reasons rather than concerns about safety or effectiveness. Children already on treatment can continue within the planned supply timelines, and our clinical team can help you understand ongoing options.

Here at the Allergy Centre of Excellence we will be offering Peanut Oral Immunotherapy, having developed a new programme to launch in April 2026.

Allergy care does not stand still. There are many ways that treatments and medical devices are improving. Some of these developments may affect how allergies are managed now or in the future. This article explains how emergency treatments such as adrenaline and other approaches have evolved over time, and what that means for people living with allergic conditions.

The Evolution of Adrenaline Treatment for Severe Allergic Reactions

For people at risk of a severe allergic reaction, quick access to adrenaline is essential. It is the first medicine recommended when symptoms of anaphylaxis begin and should be given without delay.

Early treatment methods

In the past, adrenaline was administered using a syringe and vial. This required someone to measure the dose and give the injection during an emergency. Although effective, it relied on training, confidence, and time. These factors could make treatment more difficult outside of medical settings.

Adrenaline auto-injectors

Auto-injectors such as EpiPen or Jext changed how severe allergic reactions are managed in the community. They contain a fixed dose of adrenaline and are designed to be used quickly by parents, carers, teachers, or patients themselves. These devices are now the standard emergency treatment because they allow adrenaline to be given promptly while waiting for emergency medical help.

Newer needle-free options

New treatment approaches continue to be developed to make emergency care simpler and more accessible. In 2025, a needle-free adrenaline nasal spray called EURneffy became available in the UK for people who weigh 30kg or more.

This provides another way to give adrenaline during a severe allergic reaction without using an injection. Some families find needle-free options easier to use, particularly for children who feel anxious about needles. Increasing confidence in giving adrenaline quickly can be important during an emergency.

Auto-injectors are still recommended for people who have previously needed more than one dose of adrenaline or who have experienced very severe reactions.

Research and Future Treatments

Research continues to play an important role in improving allergy care and developing new treatments for children with food allergies.

The Allergy Centre of Excellence is currently involved in the COMFORT Toddler study, a research trial looking at whether early oral immunotherapy may help young children with a peanut allergy.

The trial is designed to investigate whether introducing carefully controlled peanut oral immunotherapy in toddlers can help them safely build tolerance to peanuts at an earlier stage.

Some of the key inclusion criteria include:
• Toddlers diagnosed with peanut allergy
• Children aged between 12 and 36 months
• Participants who meet specific clinical criteria confirmed by allergy specialists

For more information about the study, visit COMFORT Toddler Study

At the moment, this is the only research study currently running through ACE. Other clinical trials are not currently open for recruitment. We encourage families who are interested in research opportunities to keep an eye on our website and our social media channels, where we will share updates about future studies.

What This Means for Families

Your child’s allergy management plan should always be tailored to their individual needs. Emergency adrenaline, whether delivered by auto-injector or in some cases by nasal spray, continues to be a critical part of that plan. Even though individual treatments such as Palforzia may change, the wider direction of allergy care is positive. Research is ongoing, new technologies are being developed, and treatment approaches continue to improve.

How ACE Supports You

At the Allergy Centre of Excellence, our focus is on safe, evidence-based care that is personalised for each patient. We take time to explain options clearly and support families in making informed decisions. If you have questions about emergency treatments, managing severe reactions, or which therapies may be suitable, our clinical team is here to help. You can contact us at any stage to review your child’s care and discuss the approach that is right for you.

Making treatment accessible is important to the team, and we are proud to offer a new way to access treatment with the Allergy Centre of Excellence – for those who have received an allergy diagnosis through the NHS or another clinic. The new Self-Referral Gateway offers fast access to expert assessment for just £450. For these patients, £150 is credited towards the OIT programme if treatment is undertaken with the team.